J&J and Boston University identify classifications to catch lung cancer

J&J and Boston University identified a subtype of precancerous lesions with genomic alterations and immune cell deficiencies that could be used to diagnose and stratify patients at the earliest stages of lung cancer.

The findings, revealed in a Nature Communications paper Tuesday, are the first published results from the partners’ precancer genome atlas (PCGA) study, which is enrolling hundreds of patients with premalignancies of the lung. PCGA is part of a five-year collaboration the Johnson & Johnson Innovation LLC unit of Johnson & Johnson (NYSE:JNJ) and Boston University began last year to identify the earliest molecular changes that lead to lung cancer to find new targets and develop interceptive products (see "J&J, Boston U Partner to Map Early Detection Biomarkers for Lung Cancer")...